NextCure Updates Antibody Drug Programs, Expects $41.8M Cash by Year-End 2025
NextCure provided updates for its two antibody drug conjugate programs and reported a preliminary year-end 2025 cash position. SIM0505: Phase 1 dose escalation data expected in Q2 2026: SIM0505 is a novel ADC directed to cadherin-6, which is overexpressed in several cancers with limited expression in healthy tissues. SIM0505 features a proprietary topoisomerase 1 inhibitor payload, designed for broad anti-tumor activity, fast systemic clearance and an improved potential therapeutic window. Data from the Phase 1 open-label dose escalation study are anticipated to be presented in the second quarter of 2026, including results from patients in the U.S. and China. The study is evaluating SIM0505 in patients with advanced solid tumors with a focus on gynecological cancers and an emphasis on platinum resistant ovarian cancer. The Company is adding clinical sites and increasing SIM0505 clinical drug supply in anticipation of initiating dose optimization in the first half of 2026. LNCB74: Ongoing Phase 1 dose escalation: LNCB74 is a novel ADC directed to B7-H4, overexpressed in several cancers with limited expression in healthy tissues. LNCB74 features a proprietary tumor-selective cleavable linker and a tubulin inhibitor monomethyl auristatin E payload. Dosing has commenced in higher dose cohorts for the ongoing open-label Phase 1 dose escalation study following the November 2025 protocol amendment announcement. Higher dose cohorts will prioritize patients with high B7-H4 expression in breast and gynecological cancers, while now including adenoid cystic carcinoma type 1. Proof-of-concept data, previously anticipated in the first half of 2026, is delayed to accommodate enrollment; NextCure now expects to provide a trial progress update in second half of 2026. As of December 31, 2025, NextCure is reporting preliminary cash, cash equivalents and marketable securities of approximately $41.8less than. These preliminary selected financial results are unaudited and subject to adjustment. The Company expects current financial resources to be sufficient to fund planned operating expenses and capital expenditures into the first half of 2027.
